Generic Imitrex Launch In U.S. Drives Strong Revenue Growth For Dr. Reddy’s
This article was originally published in PharmAsia News
Executive Summary
Mumbai - India's Dr. Reddy's Labs posted a 49 percent growth in its third quarter revenues at 18.40 billion rupees ($379 million) with strong sales coming from its generic versions of anti-migraine drug Imitrex (sumatriptan succinate) in the U.S. Dr. Reddy's registered an after tax profit of 1.92 billion rupees ($ 40 million) for the same period against a loss of $ 25 million for the third quarter of 2008